lonafarnib has been researched along with quizartinib in 1 studies
| Studies (lonafarnib) | Trials (lonafarnib) | Recent Studies (post-2010) (lonafarnib) | Studies (quizartinib) | Trials (quizartinib) | Recent Studies (post-2010) (quizartinib) |
|---|---|---|---|---|---|
| 224 | 34 | 90 | 181 | 17 | 172 |
| Protein | Taxonomy | lonafarnib (IC50) | quizartinib (IC50) |
|---|---|---|---|
| Platelet-derived growth factor receptor alpha | Homo sapiens (human) | 0.042 | |
| Vascular endothelial growth factor receptor 3 | Homo sapiens (human) | 4.9 | |
| Vascular endothelial growth factor receptor 2 | Homo sapiens (human) | 0.43 | |
| Receptor-type tyrosine-protein kinase FLT3 | Homo sapiens (human) | 0.1024 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bonovolias, ID; Chatzopoulou, M; Demopoulos, VJ; Nicolaou, I; Tsiftsoglou, AS; Vizirianakis, IS | 1 |
1 review(s) available for lonafarnib and quizartinib
| Article | Year |
|---|---|
Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.
Topics: Animals; Antineoplastic Agents; Apoptosis; Cell Differentiation; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Multipotent Stem Cells; Neoplastic Stem Cells; Pharmacogenetics | 2010 |